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journal homepage: http: / /www.elsevier .com/locate/rethLetter to the Editor4th William S Hancock award in regulatory scienceIt is our greatest honor t o inform the readers of regenerative
Therapy that Prof. Takao Hayakawa of Kinki University received
4th William S Hancock award in regulatory science. This annual
award recognizes outstanding and sustained contributions in the
ﬁeld of regulatory science. He developed his lifetime career in
biotechnology and biologics in the National Institute of Health Sci-
ences (NIHS) of Japan, serving as Division Director of Biological
Chemistry and Biologicals (1991e2002), Deputy Director General
of the NIHS (2002e2005) and an Emeritus investigator from
2005 on. He was also a senior advisor of Pharmaceutical and Med-
ical Devices Agency, PMDA (2005e2010) and still works for the
PMDA as an ad hoc advisor. He is the author or coauthor of over
550 publications in biochemistry, biotechnology, cell biology and
the pharmaceutical sciences. He is the ﬁrst and only one non-
American awardee of the award.
Dr. Hayakawa has been involved in more than 80 kinds of activ-
ities relative to public health and is still in about 40 under various
Ministries of Japan includingMinistry of Health, labour andWelfare
(MHLW), Cabinet Ofﬁce of Japan, Ministry of Education, Culture,
Sports, Science and Technology (MEXT) and Ministry of Economy,
Trade and Industry (METI). He chaired a number of committees
like Committee of Japanese Pharmacopoeia (2003e2011),Peer review under responsibility of the Japanese Society for Regenerative
Medicine.
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2352-3204/© 2015, The Japanese Society for Regenerative Medicine. Production and hoCommittee on Biotechnology Products (2003e2011) of theMHLW's
Council, and has been chairing Expert Committee on Genetically
Modiﬁed Foods (2003e2007) and followed by the Planning Expert
Committee of the Food Safety Commission of Japan. He also chaired
the Japanese Biologics Forum (2005e2011). One of his current ac-
tivities is to develop draft guidance on ensuring quality and safety
of stem cell derived products for therapeutic use. Characterization
and utilization of pluripotent stem cells for medical and pharma-
ceutical researches are the subjects of his special interest.
Congratulation! and we are proud of him.
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